Evaluation of SeroSelectTB

External quality control of the clinical trial of an innovative rapid point-of-care serological triage test for active TB.

A rapid triage test for active TB is the single biggest TB diagnostic priority advocated by the WHO strategy to end TB. KNCV is one of nine partners in the project, led by Professor Carol Holm-Hansen of the Norwegian Institute of Public Health, to evaluate the feasibility, accuracy, and effect of the SeroSelectTB rapid point-of-care serological triage test for active TB.

The test is being evaluated in high burden, HIVendemic African settings through a multi-center, parallel-group, randomized, and controlled trial. KNCV is responsible for external quality control (EQA) of the clinical trial. Major milestones in 2022 include the in-person consortium meeting, in which KNCV organized a workshop on EQA, and the start of the enrolment of participants in Tanzania and Ethiopia (Participants were enrolled in South Africa in 2021).

More about SeroSelectTB

KNCV has been fighting TB since its establishment in 1903. Over the past 120 years, the organization has acquired indispensable knowledge and experience in the field of effective TB prevention and care, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework and integrity
Our patroness
Partner with us


De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.